Highlights
- Groundbreaking Partnership: Imricor signs key licensing agreement with Swiss software firm ADIS to develop AI modules for its NorthStar 3D mapping system.
- Stock Surge: Shares rise 25% to a 52-week high of $1.34, driven by investor excitement.
- Future Impact: AI modules set to enhance MRI imaging efficiency, with a 2025 launch planned in Europe, US, and the Middle East.
Imricor Medical Systems Inc (ASX:IMR) saw its share price soar by 25%, reaching a 52-week high of AU$1.34 on Thursday, following the announcement of a transformative licensing agreement with the Swiss software company ADIS. The deal centers around the development of artificial intelligence (AI) modules that will integrate with Imricor’s cutting-edge NorthStar 3D mapping system, a breakthrough in medical imaging technology.
AI-Driven Innovation in MRI Imaging
The NorthStar system revolutionizes magnetic resonance imaging (MRI) by providing real-time image display, 3D mapping of electroanatomical data, and enhanced control over MRI scanners. The addition of AI modules, including automatic heart segmentation, will dramatically cut procedure times, reducing a 20-minute task to mere seconds, thereby improving both efficiency and accuracy for physicians.
Although these AI-enhanced modules are not yet commercially available, regulatory processes are progressing smoothly, with a projected 2025 launch across Europe, the US, and the Middle East. This advancement is poised to redefine the landscape of cardiac imaging, with Imricor positioning NorthStar as a critical tool in global MRI programs.